Navigation Links
PhaseRx Appoints Michael Houston, Ph.D., Vice President, Therapeutics Development
Date:1/10/2014

SEATTLE, Jan. 10, 2014 /PRNewswire/ -- PhaseRx, Inc., an RNA therapeutics company, today announced the appointment of Michael Houston, Ph.D., as its Vice President, Therapeutics Development.

(Logo: http://photos.prnewswire.com/prnh/20140110/SF44129LOGO)

Dr. Houston brings more than two decades of experience in the manufacturing and development of peptide and oligonucleotide-based therapeutics to PhaseRx.  He has directed numerous programs ranging from research to GMP manufacture of clinical trials materials, including nanoparticle-based delivery vehicles for siRNAs. In this new position, Dr. Houston will lead PhaseRx's therapeutics program, which focuses on the advancement of its SMARTT Polymer Technology® mRNA nanoparticles.

"Mike is a great addition to the PhaseRx team as we focus on the advancement of our SMARTT Polymer Technology RNA programs into clinical development," said Robert Overell, Ph.D., President and Chief Executive Officer at PhaseRx. "Mike's experience in the synthesis, manufacture and production of RNA therapeutics including nanoparticle-based formulations, will accelerate our efforts to apply SMARTT technology to address the significant unmet treatment need in orphan liver diseases."

Dr. Houston joins PhaseRx from Marina Biotech where he served as Vice President, Chemistry and Formulations and focused on the development of siRNAS and single stranded oligonucleotides. He has also served at Ascent Therapeutics as Vice President, Preclinical Chemistry and CMC; at MDRNA, Inc. as Vice President, Chemistry & Formulations; and at Nastech Pharmaceuticals as Senior Director, Chemistry and Formulations. Dr. Houston received a Ph.D. in bio-organic chemistry and a B.Sc. with honours in chemistry from the University of Waterloo, Ontario, Canada.

PhaseRx's SMARTT Polymer Technology (SMARTT) mediates endosome escape and mRNA delivery into cytoplasm, overcoming the key stumbling block to the delivery of mRNA drugs into cells.  SMARTT has been developed into an industrialized system that is well-tolerated in small and large animal models, does not induce innate immunity and provides robust, scalable manufacture. PhaseRx is evaluating several disease targets for SMARTT and will be selecting its lead program in 2014.

About PhaseRx
PhaseRx is privately held RNA therapeutics company developing treatments for orphan liver disease. The Company is utilizing its proprietary SMARTT Polymer Technology®, which offers the ability to deliver messenger RNA therapeutics predictably to selected tissues in vivo, thereby unlocking the value of mRNA as a new therapeutic modality. PhaseRx is headquartered in Seattle, Wash. For more information, visit www.phaserx.com.  

Contact: 
Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com                                  
206.769.9219

 


'/>"/>
SOURCE PhaseRx, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Chief Financial Officer Jonathan M. Peacock to Leave Amgen; Company Appoints Michael A. Kelly Acting Chief Financial Officer
2. Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors
3. Mylan Appoints Adele Gulfo as EVP, Global Collaboration and Strategic Operations
4. Lakewood-Amedex Inc. Appoints Geoffrey F. Cox To Its Board Of Directors
5. Kite Pharma Appoints Cynthia M. Butitta as Chief Financial Officer
6. Auspex Raises $35 Million And Appoints Industry Veteran Gerald Proehl To Its Board of Directors
7. Agile Therapeutics Appoints Dr. Elizabeth Ijeoma Onyemelukwe Garner as Chief Medical Officer
8. KaloBios Appoints Harry Lam, Ph.D. as Head of Manufacturing
9. MIMETAS Appoints BHI Entrepreneur-in-Residence Todd Chappell as General Manager, U.S. Affairs
10. Ajinomoto Althea Inc. Appoints J. David Enloe Jr. as President and Chief Executive Officer
11. Concord Medical Announces Results of 2013 Annual General Meeting; Appoints New Board Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Dec. 5, 2016   Mallinckrodt Pharmaceuticals (NYSE: ... company, today announced that it received a perfect score ... (CEI), a national benchmarking survey and report on corporate ... transgender (LGBT) workplace equality, administered by the Human Rights ... major U.S. businesses which also earned top marks this ...
(Date:12/5/2016)... , Dec. 5, 2016 Special purpose needles are ... such as fluid and cells from organs or lumps and ... and sizes. The global market for special purpose needles is ... In terms of revenue, the global special purpose needles market ... the forecast period (2016–2026) and is expected to be valued ...
(Date:12/5/2016)...   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... 2 clinical study of sotagliflozin, a dual SGLT1 and ... the leading global organization funding type 1 diabetes research. ... trial, which randomized a total of 87 patients, was ... dose of sotagliflozin compared to a placebo control in ...
Breaking Medicine Technology:
(Date:12/5/2016)... , ... December 05, 2016 , ... ... Plastic Surgery, is excited to announce the arrival of the newest Sciton laser ... with the ability to use tunable non-ablative and ablative wavelengths for exceptional results. ...
(Date:12/5/2016)... ... December 05, 2016 , ... SyncDog, Inc., the leading ... magazine, a leading online tech news platform connecting technology innovators with news, experience, ... explores the state of enterprise mobility security today, and how the SyncDog SentinelSecure™ ...
(Date:12/5/2016)... ... 05, 2016 , ... Worldwise ®, a leading consumer ... kathy ireland® Worldwide for five additional years, announced by Kevin Fick, Worldwise CEO. ... agreement three years ago to design and develop the kathy ireland® Loved Ones™ ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, ... International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February ... are honored to have Amy E. Herman present at this year’s conference, her ...
(Date:12/5/2016)... , ... December 05, 2016 , ... BSI and Brenntag ... United States and Canada for distribution of their natural fruits and beverage ... is an exciting addition to our Life Sciences product portfolio,” said Steve Brauer, ...
Breaking Medicine News(10 mins):